SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates

Abstract The new SARS-CoV-2 virus is an RNA virus that belongs to the Coronaviridae family and causes COVID-19 disease. The newly sequenced virus appears to originate in China and rapidly spread throughout the world, becoming a pandemic that, until January 5th, 2021, has caused more than 1,866,000 d...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nikolaos C. Kyriakidis, Andrés López-Cortés, Eduardo Vásconez González, Alejandra Barreto Grimaldos, Esteban Ortiz Prado
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/9fc292bcd3b4444790fed93887bc094b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9fc292bcd3b4444790fed93887bc094b
record_format	dspace
spelling	oai:doaj.org-article:9fc292bcd3b4444790fed93887bc094b2021-12-02T14:28:14ZSARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates10.1038/s41541-021-00292-w2059-0105https://doaj.org/article/9fc292bcd3b4444790fed93887bc094b2021-02-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00292-whttps://doaj.org/toc/2059-0105Abstract The new SARS-CoV-2 virus is an RNA virus that belongs to the Coronaviridae family and causes COVID-19 disease. The newly sequenced virus appears to originate in China and rapidly spread throughout the world, becoming a pandemic that, until January 5th, 2021, has caused more than 1,866,000 deaths. Hence, laboratories worldwide are developing an effective vaccine against this disease, which will be essential to reduce morbidity and mortality. Currently, there more than 64 vaccine candidates, most of them aiming to induce neutralizing antibodies against the spike protein (S). These antibodies will prevent uptake through the human ACE-2 receptor, thereby limiting viral entrance. Different vaccine platforms are being used for vaccine development, each one presenting several advantages and disadvantages. Thus far, thirteen vaccine candidates are being tested in Phase 3 clinical trials; therefore, it is closer to receiving approval or authorization for large-scale immunizations.Nikolaos C. KyriakidisAndrés López-CortésEduardo Vásconez GonzálezAlejandra Barreto GrimaldosEsteban Ortiz PradoNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-17 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Nikolaos C. Kyriakidis Andrés López-Cortés Eduardo Vásconez González Alejandra Barreto Grimaldos Esteban Ortiz Prado SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
description	Abstract The new SARS-CoV-2 virus is an RNA virus that belongs to the Coronaviridae family and causes COVID-19 disease. The newly sequenced virus appears to originate in China and rapidly spread throughout the world, becoming a pandemic that, until January 5th, 2021, has caused more than 1,866,000 deaths. Hence, laboratories worldwide are developing an effective vaccine against this disease, which will be essential to reduce morbidity and mortality. Currently, there more than 64 vaccine candidates, most of them aiming to induce neutralizing antibodies against the spike protein (S). These antibodies will prevent uptake through the human ACE-2 receptor, thereby limiting viral entrance. Different vaccine platforms are being used for vaccine development, each one presenting several advantages and disadvantages. Thus far, thirteen vaccine candidates are being tested in Phase 3 clinical trials; therefore, it is closer to receiving approval or authorization for large-scale immunizations.
format	article
author	Nikolaos C. Kyriakidis Andrés López-Cortés Eduardo Vásconez González Alejandra Barreto Grimaldos Esteban Ortiz Prado
author_facet	Nikolaos C. Kyriakidis Andrés López-Cortés Eduardo Vásconez González Alejandra Barreto Grimaldos Esteban Ortiz Prado
author_sort	Nikolaos C. Kyriakidis
title	SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
title_short	SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
title_full	SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
title_fullStr	SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
title_full_unstemmed	SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
title_sort	sars-cov-2 vaccines strategies: a comprehensive review of phase 3 candidates
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/9fc292bcd3b4444790fed93887bc094b
work_keys_str_mv	AT nikolaosckyriakidis sarscov2vaccinesstrategiesacomprehensivereviewofphase3candidates AT andreslopezcortes sarscov2vaccinesstrategiesacomprehensivereviewofphase3candidates AT eduardovasconezgonzalez sarscov2vaccinesstrategiesacomprehensivereviewofphase3candidates AT alejandrabarretogrimaldos sarscov2vaccinesstrategiesacomprehensivereviewofphase3candidates AT estebanortizprado sarscov2vaccinesstrategiesacomprehensivereviewofphase3candidates
_version_	1718391269419384832

SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates

Ejemplares similares